89bio, Inc.

NASDAQ•ETNB

CEO: Mr. Rohan Palekar

板块: Healthcare

行业: Biotechnology

上市日期: 2019-11-11

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

联系方式

142 Sansome Street, Second Floor, San Francisco, CA, 94104, United States

415-432-9270

www.89bio.com

市值

$2.20B

市盈率 (TTM)

-5.2

17.8

股息率

52周最高

$15.06

52周最低

$4.16

52周范围

98%

排名70Top 99.2%

1.1

F-Score

改良版 Piotroski 分析

基于 7 年期基本面

疲弱 • 1.1 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2019-2025

财务仪表盘

Q2 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.71+47.92%

近4季度走势

自由现金流

-$100.43M+64.19%

近4季度走势

2025 Q2 财报亮点

核心亮点

R&D Spending Rises Sharply Research and development expenses 168.3M USD for six months, up 82.4%, reflecting progression of Phase 3 ENLIGHTEN clinical trials.

Substantial Capital Raise Completed Net cash provided by financing 289.6M USD for six months, driven by 269.9M USD public offering and ATM sales.

Liquidity Position Strengthened Cash, equivalents, marketable securities 561.2M USD as of June 30, 2025, expected to fund operations for at least one year.

关注风险

Operating Losses Accelerate Significantly Net loss 182.8M USD for six months, up 83.4%; accumulated deficit reached 1.007B USD, requiring substantial future capital.

Clinical Trial Enrollment Challenges ENLIGHTEN-Fibrosis trial experiencing higher screen failures, potentially delaying expected topline histology data reporting timeline.

Israeli Tax Liability Risk Formal assessment order received from ITA asserting $26.0M tax liability plus $3.9M penalties; ultimate resolution uncertain.

前瞻展望

SHTG Topline Data Expected Q1 2026 Expect to report topline data from the ENTRUST Phase 3 SHTG trial in the first quarter of 2026, following study completion.

MASH Phase 3 Data Milestones ENLIGHTEN-Fibrosis histology topline data anticipated H1 2027; ENLIGHTEN-Cirrhosis data expected in 2028 for F4 patients.

ATM Facility Remaining Capacity Approximately $82.8M remains available for future common stock sales under the 2023 ATM Facility for liquidity management.

同行对比

营业收入 (TTM)

GLPG

$1.26B

+303.5%

TVTX

$490.73M

+110.5%

RCUS

$247.00M

-4.3%

毛利率 (最新季度)

LQDA

101.7%

+29.3pp

AGIO

96.9%

-4.3pp

BEAM

95.0%

-471.3pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
IBRX	$9.21B	-25.2	64.3%	175.0%
COGT	$6.08B	-7.7	-100.2%	27.0%
DNLI	$3.08B	-6.7	-50.1%	3.7%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据